Table 2 |
|
|
Inclusion criteria for HCS transplantation in various autoimmune diseases |
|
| Disease/ |
|
| general |
|
| principles |
Criteria |
|
|
|
| General |
Failed best available conventional therapy |
| Progressive disease, poor prognosis (for life or organ) |
|
| Reasonable quality of life if autoimmune disease activity |
|
| were arrested |
|
| <60 years old |
|
| Able to withstand HSC transplantation (especially |
|
| cyclophosphamide 4 g/m2) |
|
| SSc |
Diffuse skin disease for <3 years and progressive plus |
| other organ involvement |
|
| Modified Rodnan >16 (max 51) |
|
| Diffuse skin disease for >3 years or limited skin and vital |
|
| organ involvement (threatening) |
|
| Mean PAP <50 mmHg, DLCO >45% predicted |
|
| LVEF >50% of normal (on echo), >45% MUGA |
|
| Controlled arrhythmias |
|
| Hypertension controlled by ACE inhibitors |
|
| Serum creatinine <1.5 times normal upper limit |
|
| RA |
Failed: two DMARDS (including methotrexate) + any |
| combination of DMARDS + anti-TNF regimen |
|
| Progressive destruction |
|
| Disease duration 2-10 years |
|
| MS |
Disease duration ≥ 1 year |
| EDSS between 3.0 and 6.5 |
|
| Disability progression sustained for at least 6 months |
|
| during the previous 2 years of: |
|
| ≥ 1.5 EDSS points if entry EDSS between 3.0 and 5.0 |
|
| ≥ 1.0 EDSS point if entry EDSS ≥ 5.5 |
|
| Primary or secondary progressive MS |
|
| Clinical or MRI activity during the past year |
|
|
|
|
|
ACE, angiotensin-converting enzyme; DLCO, lung diffusion capacity; DMARD, disease-modifying antirheumatic drug; EDSS, extended disability score system; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; MUGA, multigated image acquisition; PAP, pulmonary artery pressure; TNF, tumour necrosis factor. |
|
|
Tyndall and Gratwohl Arthritis Res 2000 2:276 doi:10.1186/ar102 |
|